×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Arthritis | arthritis | drug | chronic | pain | trial

Drug for Arthritis Pain Clears Late-Stage Trial

Drug for Arthritis Pain Clears Late-Stage Trial
(Copyright AP)

Monday, 02 May 2016 12:09 PM

Drugmaker Regeneron Pharmaceuticals Inc said on Monday its experimental drug to treat moderate-to-severe osteoarthritis pain was successful in a late-stage study.

The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current pain killers.

After 16 weeks, patients given fasinumab reported less pain, as measured on a physician-grade scale, than those given a placebo, Regeneron said in a statement.

Current treatments for pain management include non-steroidal anti-inflammatory drugs, anti-seizure agents, and opiates. However, these drugs cause multiple side-effects and often prove to be toxic with long-term use.

Fasinumab binds to nerve growth factor (NGF) proteins and block their activity, reducing pain.

A number of companies, including Pfizer Inc and Eli Lilly & Co, are developing drugs that target NGFs.

The U.S. Food and Drug Administration placed fasinumab and other experimental agents targeting NGF on partial clinical hold in December 2012 after reports that animals treated with these drugs had nerve damage.

Fasinumab is no longer on clinical hold, according to Regeneron's website.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
Drugmaker Regeneron Pharmaceuticals Inc said on Monday its experimental drug to treat moderate-to-severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to...
arthritis, drug, chronic, pain, trial
170
2016-09-02
Monday, 02 May 2016 12:09 PM
Newsmax Media, Inc.
More Articles
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved